Table 2.

Myocarditis and pericarditis events reported to Vaccine Adverse Event Reporting System (VAERS) overall Datalock point 14 March 2022

Age group	Myocarditis								Pericarditis
	Male		Female		Sex not specified		Total		Male		Female		Sex not specified		Total
	n	%	n	%	n	%	n	%	n	%	n	%	n	%	N	%
Comirnaty (PfizerBioNTech)
<6 months	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	1	0.23	0	0.00	1	0.09
3–5 years	2	0.15	0	0.00	0	0.00	2	0.11	1	0.14	0	0.00	0	0.00	1	0.09
6–17 years	525	38.80	67	15.44	2	5.41	594	32.57	145	20.14	23	5.32	1	10.00	169	14.54
18–29 years	404	29.86	102	23.50	1	2.70	507	27.80	217	30.14	51	11.81	0	0.00	268	23.06
30–39 years	157	11.60	69	15.90	2	5.41	228	12.50	116	16.11	78	18.06	0	0.00	194	16.70
40–49 years	68	5.03	59	13.59	0	0.00	127	6.96	56	7.78	83	19.21	0	0.00	139	11.96
50–59 years	41	3.03	56	12.90	0	0.00	97	5.32	64	8.89	73	16.90	0	0.00	137	11.79
60–64 years	13	0.96	21	4.84	2	5.41	36	1.97	20	2.78	43	9.95	0	0.00	63	5.42
65–79 years	52	3.84	31	7.14	2	5.41	85	4.66	67	9.31	50	11.57	2	20.00	119	10.24
80+ years	5	0.37	4	0.92	0	0.00	9	0.49	12	1.67	9	2.08	0	0.00	21	1.81
Not specified	86	6.36	25	5.76	28	75.68	139	7.62	22	3.06	21	4.86	7	70.00	50	4.30
Total	1353	100.00	434	100.00	37	100.00	1824	100.00	720	100.00	432	100.00	10	100.00	1162	100.00
Spikevax (Moderna)
<6 months	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00
3–5 years	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00
6–17 years	5	0.78	1	0.37	2	10.53	8	0.86	1	0.26	0	0.00	0	0.00	1	0.14
18–29 years	317	49.15	64	23.79	1	5.26	382	40.94	130	33.33	62	20.39	0	0.00	192	27.16
30–39 years	135	20.93	51	18.96	0	0.00	186	19.94	59	15.13	38	12.50	1	7.69	98	13.86
40–49 years	62	9.61	51	18.96	0	0.00	113	12.11	57	14.62	54	17.76	0	0.00	111	15.70
50–59 years	41	6.36	37	13.75	1	5.26	79	8.47	52	13.33	52	17.11	0	0.00	104	14.71
60–64 years	15	2.33	24	8.92	0	0.00	39	4.18	24	6.15	31	10.20	1	7.69	56	7.92
65–79 years	29	4.50	35	13.01	0	0.00	64	6.86	54	13.85	53	17.43	2	15.38	109	15.42
80+ years	5	0.78	4	1.49	0	0.00	9	0.96	6	1.54	11	3.62	0	0.00	17	2.40
Not Specified	36	5.58	2	0.74	15	78.95	53	5.68	7	1.79	3	0.99	9	69.23	19	2.69
Total	645	100.00	269	100.00	19	100.00	933	100.00	390	100.00	304	100.00	13	100.00	707	100.00
Overall (both mRNA vaccines)
<6 months	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	1	0.14	0	0.00	1	0.05
3–5 years	2	0.10	0	0.00	0	0.00	2	0.07	1	0.09	0	0.00	0	0.00	1	0.05
6–17 years	530	26.53	68	9.67	4	7.14	602	21.84	146	13.15	23	3.13	1	4.35	170	9.10
18–29 years	721	36.09	166	23.61	2	3.57	889	32.25	347	31.26	113	15.35	0	0.00	460	24.61
30–39 years	292	14.61	120	17.07	2	3.57	414	15.02	175	15.77	116	15.76	1	4.35	292	15.62
40–49 years	130	6.51	110	15.65	0	0.00	240	8.71	113	10.18	137	18.61	0	0.00	250	13.38
50–59 years	82	4.10	93	13.23	1	1.79	176	6.38	116	10.45	125	16.98	0	0.00	241	12.89
60–64 years	28	1.40	45	6.40	2	3.57	75	2.72	44	3.96	74	10.05	1	4.35	119	6.37
65–79 years	81	4.05	66	9.39	2	3.57	149	5.40	121	10.90	103	13.99	4	17.39	228	12.20
80+ years	10	0.50	8	1.14	0	0.00	18	0.65	18	1.62	20	2.72	0	0.00	38	2.03
Not specified	122	6.11	27	3.84	43	76.79	192	6.96	29	2.61	24	3.26	16	69.57	69	3.69
Total	1998	100.00	703	100.00	56	100.00	2757	100.00	1110	100.00	736	100.00	23	100.00	1869	100.00
Grand total	1998	72.47	703	25.50	56	2.03	2757	100.00	1110	59.39	736	39.38	23	1.23	1869	100.00

Percentages per age group are presented.

mRNA, messenger RNA.